Mirae Asset Global Investments
KROS icon

Mirae Asset Global Investments’s Keros Therapeutics KROS Stock Holding History

Mirae Asset Global Investments’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.47K Sell
885
-704
-44% -$7.84K ﹤0.01% 1576
2026
Q1 		$17.5K Buy
1,589
+109
+7% +$1.68K ﹤0.01% 1448
2025
Q4 		$30.1K Sell
1,480
-90
-6% -$1.58K ﹤0.01% 1487
2025
Q3 		$24.8K Buy
1,570
+1
+0.1% +$15 ﹤0.01% 1467
2025
Q2 		$20.9K Buy
1,569
+209
+15% +$2.82K ﹤0.01% 1395
2025
Q1 		$14.7K Buy
1,360
+10
+0.7% +$116 ﹤0.01% 1423
2024
Q4 		$22.2K Sell
1,350
-7
-0.5% -$364 ﹤0.01% 1407
2024
Q3 		$76.6K Buy
1,357
+280
+26% +$13.8K ﹤0.01% 1230
2024
Q2 		$48.5K Sell
1,077
-12,072
-92% -$649K ﹤0.01% 1256
2024
Q1 		$662K Buy
13,149
+251
+2% +$14.9K ﹤0.01% 1766
2023
Q4 		$513K Buy
12,898
+404
+3% +$12.7K ﹤0.01% 1956
2023
Q3 		$398K Buy
12,494
+950
+8% +$35.5K ﹤0.01% 1997
2023
Q2 		$463K Buy
11,544
+5
+0% +$219 ﹤0.01% 1981
2023
Q1 		$493K Buy
+11,539
New +$583K ﹤0.01% 1931

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Mirae Asset Global Investments's KROS Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Keros Therapeutics (KROS) stake by 44% in Q2 2026, selling an estimated $7.84K and leaving 885 shares worth $9.47K. The position accounts for ﹤0.01% of the portfolio, ranked #1576.

Mirae Asset Global Investments first reported a position in KROS in Q1 2023 and has held it in 14 quarters since. The position peaked at $662K in Q1 2024. 35 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Mirae Asset Global Investments held 885 shares of Keros Therapeutics worth $9.47K as of Q2 2026.
  • Mirae Asset Global Investments sold 704 Keros Therapeutics shares in Q2 2026, an estimated $7.84K.
  • Keros Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1576 holding.
  • Mirae Asset Global Investments first reported a position in Keros Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Mirae Asset Global Investments's Keros Therapeutics position peaked at $662K in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.